US 8,653,263

Application 13/503,231 · Granted Feb 18, 2014

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Estimated expiration

October 21, 2030

3y 335d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Oct 21, 2010
+ 20 years
Oct 21, 2030
PTA +0d
Oct 21, 2030
No TD
—
Final
Oct 21, 2030

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
April 20, 2012
Earliest effective filing
October 21, 2010
Issue date
February 18, 2014
PTA
0 days
Base expiry (before PTA)
October 21, 2030

October 21, 2010 + 20 years = October 21, 2030

  • National stage entry of application PCTUS2010053606, filed Oct 21, 2010
  • PRO61/254,509 — Provisional — not used for base term
  • PRO61/254,509 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/503,231 · US 8,653,263

PatentReply compiles the prosecution history behind US 8,653,263: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US8653263

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.